JMP Securities Reiterates Market Outperform on Altimmune, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Jonathan Wolleben has reiterated a 'Market Outperform' rating on Altimmune (NASDAQ:ALT) and maintained a $15 price target.
July 12, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Altimmune's stock rating has been reiterated as 'Market Outperform' by JMP Securities with a maintained price target of $15.
The reiteration of the 'Market Outperform' rating and the maintenance of the $15 price target by JMP Securities indicates a positive outlook for Altimmune. This could potentially lead to an increase in investor confidence and a positive impact on the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100